Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 20/20 | 0.91 |
| ▸ | CPT1B | Q92523 | 18/20 | 0.91 |
| ▸ | CPT2 | P23786 | 11/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014606 | 0.95 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL3580255 | 0.95 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL3569307 | 0.94 | CPT1A (0.88) | CPT1ACPT1BCPT2 | |
| SCHEMBL3572886 | 0.92 | CPT1A (0.80) | CPT1ACPT1BCPT2 | |
| SCHEMBL2900821 | 0.92 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL30015415 | 0.91 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL3575579 | 0.91 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL3578735 | 0.90 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL3585181 | 0.90 | CPT1A (0.88) | CPT1ACPT1BCPT2 | |
| SCHEMBL30015649 | 0.90 | CPT1A (1.00) | CPT1ACPT1BCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022212568-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | CPT1A 15/4885CPT1B 50/4885CPT2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.